Psychogenics, Inc.
Publicly observedParamus, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Paramus | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Psychogenics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | YXMNA8N7LFG4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Jun 2026Publicly observed
NIH SBIR/STTR award: TAAR1 Agonists for the Treatment of Stimulant Use Disorder
USD 398,947.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of a Drug Candidate for the Treatment of Agitation in Alzheimer's Disease
USD 495,699.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant5 Aug 2024Publicly observed
NIH SBIR/STTR award: EEG Signature Analysis for Drug Repurposing for Rare Diseases
USD 924,001.00 · National Institute of Mental Health · Source: NIH RePORTER (opens in a new tab)
- Grant5 Aug 2024Publicly observed
NIH SBIR/STTR award: EEG Signature Analysis for Drug Repurposing for Rare Diseases
USD 460,234.00 · National Institute of Mental Health · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.